The so called new Immune Response BioPharma company that claims to now own the research from Immune Response/Orchestra Therapeutics has now annouced that it has started a new unit called,(you guessed it) Orchestra Therapeutics. It claims Orchestra Therapeutics will focus on the development of new antibiotics and manufacturing of Generic antibiotics. Can you believe that? First they claim to be a whole new company and call themselves Immune Response BioPharma. Only this so called new company's claim to fame is the fact that they say they now own the rights to all the research of another company by the name of (you guessed it) Immune Response Corporation. Now they claim to be starting a new unit by the name of (you guessed it again) Orchestra Therapeutics which just happens to be the name that Immune Response Corporation changed to and still trades under as OCHTQ.PK. Apparently the primary goal of David Buswell and his accomplices is too not only steal the research financed by the investors in IMNR/OCHTQ.PK, but also to steal the names as well. I can't figure out if they know they are running a scam and aren't worried about the long term outcome of their actions or if they think that investors will be so blind as to not see that these companies are all one and the same. The only thing different is that insiders have tried to manipulate the original companies so that they could cheat the original investors, steal the research, and make all the profits. | |
A blog maintained by an investor in Immune Response Corporation now called Orchestra Therapeutics, Inc. (OCHTQ.PK). Immune Response BioPharma claims to now own the research and trial results from Immune Response and is attempting to market their findings through the Immune Response BioPharma name.
Tuesday, October 18, 2011
Wednesday, October 5, 2011
Immune Response BioPharma Stock
I purchased another 3000 shares of Orchestra Theraputic (OCHTQ.PK) today. It is important that stock holders in Immune Response/Orchestra Therap keep the stock active to help protect our rights and to make sure it stays active on the trading boards.
Subscribe to:
Posts (Atom)